BioCentury
ARTICLE | Clinical News

Shorter ABT-493/ABT-530 regimen yields 100% SVR4

October 21, 2015 12:57 AM UTC

An abstract released ahead of the American Association for the Study of Liver Diseases (AASLD) meeting showed an eight-week regimen of ABT-493 from AbbVie Inc. (NYSE:ABBV) and Enanta Pharmaceuticals Inc. (NASDASQ:ENTA) plus AbbVie's ABT-530 led to an SVR4 rate of 100% in 34 non-cirrhotic HCV genotype 1 patients.

The Phase II SURVEYOR-I trial included both treatment-naive and previously treated patients. All patients received 300 mg of ABT-493 and 120 mg of ABT-530 once-daily for eight weeks. ABT-493 is a next-generation HCV NS3/4A protease inhibitor and ABT-530 is an HCV HS5A protein inhibitor. SVR12 data from the study will be presented at the AASLD meeting in November. ...